Skip to nav Skip to content

We specialize in the evaluation and treatment of patients referred for blood and marrow stem cell transplants. Diseases treated:

  • Adult inherited immunodeficiencies
  • Essential thrombocytosis (ET)
  • Leukemia (acute and chronic)
  • Lymphoma (Hodgkin and non-Hodgkin)
  • Multiple myeloma 
  • Myelodysplastic syndromes (MDS)
  • Myelofibrosis
  • Myeloproliferative neoplasms
  • Paroxysmal nocturnal hemoglobinuria (PNH)
  • Primary amyloidosis
  • Severe anaplastic anemia (SAA)
  • Sickle cell disease/anemia
    • For patients with sickle cell and an available donor, doctors might recommend a transplant if the patient has one of the following: 
      • More than three severe pain crises within two years
      • A stroke or silent stroke
      • Acute chest syndrome two or more times in the last two years
      • Eight or more red blood cell transfusions per year
      • Pulmonary hypertension
      • Chronic pain lasting longer than six months
      • Ultrasounds that show a high risk for having a stroke
      • Other severe complications of sickle cell
  • Testicular cancer
  • Waldenström’s macroglobulinemia
  • Other hematologic diseases

Moffitt Cancer Center is a high-volume center, delivering more FDA-approved CAR T cell products than any other center in the nation. Current indications for CAR T cells are for patients with relapsed or refractory blood cancers, including: 

Diseases Treated with Cellular therapy (FDA-Approved)

  • Acute lymphoblastic leukemia 
  • B-cell non-Hodgkin lymphoma
  • Follicular lymphoma  
  • Mantle cell lymphoma  
  • Multiple myeloma  

Diseases Treated with Stem Cell Transplant and Cellular Therapy

Indications for Allogeneic Hematopoietic Stem Cell Transplant 

  • Acute myeloid leukemia 
  • Acute promyelocytic leukemia 
  • Acute lymphoblastic leukemia 
  • Chronic myeloid leukemia 
  • Myelodysplastic syndromes 
  • Myelofibrosis and myeloproliferative diseases 
  • Systemic mastocytosis 
  • Blastic plasmacytoid dendritic cell neoplasm 
  • Hodgkin lymphoma 
  • Diffuse large B cell lymphoma 
  • Follicular lymphoma 
  • Mantle cell lymphoma 
  • T-cell lymphoma 
  • Chronic lymphocytic leukemia 

Indications for Autologous Hematopoietic Stem Cell Transplant 

  • Multiple myeloma 
  • Hodgkin lymphoma 
  • Diffuse large B cell lymphoma 
  • Primary central nervous system lymphoma 
  • Follicular lymphoma 
  • Mantle cell lymphoma 
  • T-cell lymphoma 
  • Waldenstrom macroglobulinemia 
  • Burkitt lymphoma 
  • Germ cell tumor 

Indications for Hematopoietic Stem Cell Transplant for Non-Malignant Conditions 

  • Severe aplastic anemia 
  • Pure red cell aplasia 
  • Thalassemia 
  • Sickle cell anemia 
  • Common variable immunodeficiency 
  • Multiple sclerosis 
  • Chronic granulomatous disease   

Indications for Immune Effector Cell Therapy (FDA approved) 

  • Acute lymphoblastic leukemia 
  • Diffuse large B cell lymphoma 
  • Primary mediastinal B cell lymphoma 
  • High-grade B cell lymphoma 
  • Follicular lymphoma 
  • Mantle cell lymphoma 
  • Multiple myeloma 

Medically reviewed by Omar Castaneda Puglianini, MD